Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer
Anticancer Research · 2025
DOI: 10.21873/anticanres.17847 ↗Kurz gefasst
Fallbericht in der Zeitschrift Anticancer Research, 2025. Verfasst von Ayumu Hosokawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan; ayhosoka@med.miyazaki-u.ac.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Rectal Neoplasms, Microsatellite Instability, DNA Mismatch Repair.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan; ayhosoka@med.miyazaki-u.ac.jp.
- Department of Cell Pathology, Graduate School of Medicine, Kumamoto University, Kumamoto, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
- Department of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan.
- Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki, Japan.
- Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Zitieren
APA
Hosokawa, A., Yamada, R., Otsuki, Y., Tamura, H., Ichihara, A., Fukushima, T., & Komohara, Y. (2025). Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.17847
Vancouver
Hosokawa A, Yamada R, Otsuki Y, Tamura H, Ichihara A, Fukushima T, et al. Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer. Anticancer Research. 2025. doi:10.21873/anticanres.17847
BibTeX
@article{Hosokawa2025,
author = {Hosokawa, Ayumu and Yamada, Rin and Otsuki, Yukiko and Tamura, Hotaka and Ichihara, Akiko and Fukushima, Tsuyoshi and Komohara, Yoshihiro},
title = {Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17847}
}
EUVIMED